(3-{[(5-dec-1-yn-1-ylquinolin-8-yl)methyl]amino}propyl)phosphonic acid;
[3-({[5-(7-phenylhept-1-yn-1-yl)quinolin-8-yl]methyl}amino)propyl]phosphonic acid;
[3-({[5-(6-phenylhex-1-yn-1-yl)quinolin-8-yl]methyl}amino)propyl]phosphonic acid;
[3-({[5-(7-phenylheptyl)quinolin-8-yl]methyl}amino)propyl]phosphonic acid;
(3-{[(5-dec-1-yn-1-ylquinolin-8-yl)methyl]amino}butyl)phosphonic acid;
[3-({[5-(6-phenylhexyl)quinolin-8-yl]methyl}amino)propyl]phosphonic acid;
[3-({[5-(5-phenylpent-1-yn-1-yl)quinolin-8-yl]methyl}amino)propyl]phosphonic acid;
[3-({[5-(5-phenylpentyl)quinolin-8-yl]methyl}amino)propyl]phosphonic acid;
2-({[5-(6-phenylhexyl)quinolin-8-yl]methyl}amino)ethanol;
2-({[5-(6-phenylhexyl)quinolin-8-yl]methyl}amino)ethyl dihydrogen phosphate;
{3-[({5-[6-(3-methoxyphenyl)hex-1-yn-1-yl]quinolin-8-yl}methyl)amino]propyl}phosphonic acid;
{3-[({5-[6-(3-methoxyphenyl)hexyl]quinolin-8-yl}methyl)amino]propyl}phosphonic acid;
{3-[({5-[6-(3-methoxyphenyl)hexyl]-5,6,7,8-tetrahydroquinolin-8-yl}methyl)amino]propyl}phosphonic acid ;
{3-[({4-[(1E)-dec-1-en-1-yl]-1-naphthyl}methyl)amino]propyl}phosphonic acid;
[3-({[4-(6-phenylhex-1-yn-1-yl)-1-naphthyl]methyl}amino)propyl]phosphonic acid;
2-({[4-(6-phenylhexyl)-1-naphthyl]methyl}amino)ethanol;
2-({[4-(6-phenylhexyl)-1-naphthyl]methyl}amino)ethyl dihydrogen phosphate;
[3-({[4-(6-phenylhexyl)-1-naphthyl]methyl}amino)propyl]phosphonic acid;
{3-[({4-[6-(3-methoxyphenyl)hex-1-yn-1-yl]-1-naphthyl}methyl)amino]propyl}phosphonic acid;
2-[({4-[6-(3-methoxyphenyl)hex-1-yn-1-yl]-1-naphthyl}methyl)amino]ethyl dihydrogen phosphate;
{3-[({4-[6-(3-methoxyphenyl)hexyl]-1-naphthyl}methyl)amino]propyl}phosphonic acid;
2-[({4-[6-(3-methoxyphenyl)hexyl]-1-naphthyl}methyl)amino]ethanol;
2-[({4-[6-(3-methoxyphenyl)hexyl]-1-naphthyl}methyl)amino]ethyl dihydrogen phosphate.

11. ~~A method of treating a disorder associated with sphingosine-1-phosphate receptor modulation, which comprises administering to a mammal in need thereof,~~ Use of a

pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I

R^{10} is H or substituted or unsubstituted C_{1-3} alkyl;

R^{11} is H or substituted or unsubstituted C_{1-3} alkyl;

L^1 is O, S, NH or CH_2;


L^2 is O, S, NH or CH_2;


a is 0 or 1;


b is 0, 1, 2 or 3;


c is 1, 2, 3 or 4;


d is 1, 2 or 3; with the provisos


when a is 1 then  represents


 ; or

 ; or

 ; or

 ; or

 ; or

 ; and

when a is 0 then R^1 is O, S, NH, or CH_2 in the manufacture of a medicament for treating a disorder associated with sphingosine-1-phosphate receptor modulation, wherein the medicament is to be administered to a mammal in need thereof.

12. ~~A method~~The use of claim 11, wherein the ~~pharmaceutical composition~~ medicament is to be administered to the mammal to treat ocular diseases, wet and dry age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal edema, geographic atrophy, glaucomatous optic neuropathy, chorioretinopathy, hypertensive retinopathy, ocular ischemic syndrome, prevention of inflammation-induced fibrosis in the back of the eye, various ocular inflammatory diseases including uveitis, scleritis, keratitis, and retinal vasculitis; or systemic vascular barrier related diseases, various inflammatory diseases, including acute lung injury, its prevention, sepsis, tumor metastasis, atherosclerosis, pulmonary edemas, and ventilation-induced lung injury; or autoimmune diseases and immunosuppression, rheumatoid arthritis, Crohn's

disease, Graves' disease, inflammatory bowel disease, multiple sclerosis, Myasthenia gravis, Psoriasis, ulcerative colitis, antoimmune uveitis, renal ischemia perfusion injury, contact

hypersensitivity, atopic dermititis, and organ transplantation; or allergies and other inflammatory diseases, urticaria, bronchial asthma, and other airway inflammations including pulmonary emphysema and chronic obstructive pulmonary diseases; or cardiac protection, ischemia reperfusion injury and atherosclerosis; or wound healing such as but not limited to: scar-free healing of wounds from cosmetic skin surgery, ocular surgery, GI surgery, general surgery, oral injuries, various mechanical, heat and burn injuries, prevention and treatment of photoaging and skin ageing, and prevention of radiation-induced injuries; or bone formation, treatment of osteoporosis and various bone fractures including hip and ankles; or anti-nociceptive activity, visceral pain, pain associated with diabetic neuropathy, rheumatoid arthritis, chronic knee and joint pain, tendonitis, osteoarthritis, neuropathic pains; or central nervous system neuronal activity in Alzheimer's disease, age-related neuronal injuries; or organ transplant such as renal, corneal, cardiac or adipose tissue transplant.

13. The ~~method~~ use of claim 12 wherein the mammal is a human.